Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
32 hedge funds and large institutions have $185M invested in Carisma Therapeutics in 2014 Q1 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
+$72.5M |
| 2 |
FV2GP
Flagship Ventures 2007 General Partner
Cambridge,
Massachusetts
|
+$28.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.2M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$14M |
| 5 |
BC
Broadfin Capital
New York
|
+$12.9M |
Top Sellers
CARM Hedge Fund Activity: Q1 2014 in Review
32 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2014, worth a combined $185M.
Buyers outnumbered sellers: 32 funds opened new CARM positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Third Rock Ventures, opening a new position worth an estimated $72.5M.
- 32 institutional investors held Carisma Therapeutics (CARM) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $185M of Carisma Therapeutics stock for Q1 2014.
- 32 funds opened new Carisma Therapeutics positions in Q1 2014 and 0 closed out, a net change of +32 holders.
- The largest Carisma Therapeutics buyer in Q1 2014 was Third Rock Ventures, an estimated $72.5M added.
Based on aggregated 13F filings for Q1 2014.